Open AccessGlioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial
Author(s) -
Shiao Pei Weathers,
Marta PenasPrado,
Be Lian Pei,
Xiaoyang Ling,
Cynthia Kassab,
Pinaki P. Banerjee,
Mustafa Bdiwi,
Hila Shaim,
Abdullah Alsuliman,
Mayra Shanley,
John F. de Groot,
Barbara O’Brien,
Rebecca Harrison,
Nazanin Majd,
Carlos Kamiya-Matsuoka,
Gregory N. Fuller,
Jason T. Huse,
Linda Chi,
Ganesh Rao,
Jeffrey S. Weinberg,
Frederick F. Lang,
Raymond Sawaya,
Elizabeth J. Shpall,
Katayoun Rezvani,
Amy B. Heimberger
Publication year - 2020
Publication title -
clinical cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.427
H-Index - 324
eISSN - 1557-3265
pISSN - 1078-0432
DOI - 10.1158/1078-0432.ccr-20-0176
Subject(s) - leukapheresis , temozolomide , medicine , cd8 , immunology , immune system , cytotoxic t cell , immunotherapy , antigen , chemotherapy , gastroenterology , biology , cd34 , in vitro , biochemistry , genetics , stem cell
Cytomegalovirus (CMV) antigens occur in glioblastoma but not in normal brains, making them desirable immunologic targets.